logo
  

FDA Approves GE Healthcare's Software For General Anesthesia Delivery

GE Healthcare, a healthcare arm of General Electric (GE), said on Monday that it has received pre-market approval from the FDA for its End-tidal Control software to assist in the automated delivery of anesthesia and the reduction of greenhouse gas emissions during surgery.

The End-tidal (Et) Control software will be used in the company's Aisys CS2Anesthesia Delivery System.

GE Healthcare will launch the Aisys CS2 Anesthesia Delivery System with the Et Control software in the U.S. in the upcoming months.

The approval was based on the results from the U.S.-based, multi-center, multi-year MASTER-Anesthesia Trial, in which the safety and effectiveness of the Et Control software were evaluated against conventional anesthetic gas delivery methods during general anesthesia in over 200 patients.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Delta Air Lines is set to resume flights on its routes between the U.S. and Japan from October 30, 2002 in anticipation of easing of COVID-19-related travel restrictions, which were put in place two years ago. The airline joins American Airlines and United Airlines, who have reportedly announced the resumption of flights to Japan. Tech major Apple Inc. has asked corporate employees to return to offices at least three days a week by September 5, Bloomberg reported. The latest deadline was issued following several delays to its previous deadlines amid a resurgence in COVID-19 cases. As per the report, the company will require employees to work from offices on Tuesdays, Thursdays and a regular third day to be determined by... Retail giant Walmart reported Tuesday a net profit for the second quarter that grew 20.4 percent from last year, reflecting lower operating expenses and partially inflation driven revenue growth. The results were also driven by the rebound in international markets. Quarterly revenues topped analysts' expectations. The retailer also raised its adjusted earnings guidance for the full-year 2023.
Follow RTT